Omeros Corporation (NASDAQ:OMER) received a $19.00 target price from Maxim Group in a report released on Wednesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective suggests a potential upside of 46.27% from the company’s current price.
Several other research firms also recently commented on OMER. Cantor Fitzgerald reiterated a “buy” rating and issued a $21.00 price objective on shares of Omeros Corporation in a report on Wednesday, August 10th. Wedbush reiterated an “outperform” rating and issued a $56.00 price objective (down previously from $62.00) on shares of Omeros Corporation in a report on Thursday, August 11th. Zacks Investment Research downgraded Omeros Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, July 13th. FBR & Co reiterated an “outperform” rating and issued a $38.00 price objective on shares of Omeros Corporation in a report on Tuesday, October 18th. Finally, S&P Equity Research lifted their price objective on Omeros Corporation from $7.65 to $8.63 in a report on Monday, October 17th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $33.23.
Omeros Corporation (NASDAQ:OMER) traded up 1.88% on Wednesday, reaching $12.99. The company had a trading volume of 264,814 shares. The company’s 50 day moving average is $9.87 and its 200-day moving average is $10.86. The firm’s market capitalization is $557.48 billion. Omeros Corporation has a one year low of $7.20 and a one year high of $16.80.
Omeros Corporation (NASDAQ:OMER) last announced its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.06. The company had revenue of $11.30 million for the quarter, compared to the consensus estimate of $11.64 million. During the same period last year, the business posted ($0.53) earnings per share. The firm’s quarterly revenue was up 253.1% compared to the same quarter last year. On average, equities research analysts expect that Omeros Corporation will post ($1.69) earnings per share for the current fiscal year.
In other Omeros Corporation news, VP Marcia S. Kelbon sold 16,000 shares of the company’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $10.91, for a total transaction of $174,560.00. Following the transaction, the vice president now owns 179,597 shares in the company, valued at approximately $1,959,403.27. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 13.60% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Fund Advisors increased its position in Omeros Corporation by 0.7% in the first quarter. BlackRock Fund Advisors now owns 1,471,968 shares of the biopharmaceutical company’s stock worth $22,580,000 after buying an additional 10,605 shares during the period. UBS Group AG boosted its stake in shares of Omeros Corporation by 0.8% in the first quarter. UBS Group AG now owns 333,744 shares of the biopharmaceutical company’s stock worth $5,120,000 after buying an additional 2,631 shares in the last quarter. Bank of Montreal Can bought a new stake in shares of Omeros Corporation during the second quarter worth approximately $17,641,000. Chicago Equity Partners LLC bought a new stake in shares of Omeros Corporation during the second quarter worth approximately $961,000. Finally, Bourgeon Capital Management LLC bought a new stake in shares of Omeros Corporation during the second quarter worth approximately $158,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.
Omeros Corporation Company Profile